Ewing sarcoma: Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future

Joseph A. Ludwig

doi:10.1097/CCO.0b013e328303ba1d

Ewing sarcoma: Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future

Joseph A. Ludwig

Sarcoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

178 Scopus citations

Abstract

With an improved understanding of the genome, transcriptome, proteome, and other '-omic' events that promote and sustain Ewing pathogenesis, the use of nascent biologically targeted therapeutics is on the horizon. Understanding how and when to integrate such therapies into clinical practice, although challenging, may lead to a paradigm shift towards more personalized therapy.

Original language	English (US)
Pages (from-to)	412-418
Number of pages	7
Journal	Current opinion in oncology
Volume	20
Issue number	4
DOIs	https://doi.org/10.1097/CCO.0b013e328303ba1d
State	Published - Jul 2008

Keywords

Biomarkers
Cancer
Ewing's sarcoma
IGF-1R
Molecular markers
Phase II trials
Prognosis
Sarcoma
Staging
Targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/CCO.0b013e328303ba1d

Cite this

@article{b0854b248dcb48ea8573f7fd5a88c4ac,

title = "Ewing sarcoma: Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future",

abstract = "With an improved understanding of the genome, transcriptome, proteome, and other '-omic' events that promote and sustain Ewing pathogenesis, the use of nascent biologically targeted therapeutics is on the horizon. Understanding how and when to integrate such therapies into clinical practice, although challenging, may lead to a paradigm shift towards more personalized therapy.",

keywords = "Biomarkers, Cancer, Ewing's sarcoma, IGF-1R, Molecular markers, Phase II trials, Prognosis, Sarcoma, Staging, Targeted therapy",

author = "Ludwig, {Joseph A.}",

year = "2008",

month = jul,

doi = "10.1097/CCO.0b013e328303ba1d",

language = "English (US)",

volume = "20",

pages = "412--418",

journal = "Current opinion in oncology",

issn = "1040-8746",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Ewing sarcoma

T2 - Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future

AU - Ludwig, Joseph A.

PY - 2008/7

Y1 - 2008/7

N2 - With an improved understanding of the genome, transcriptome, proteome, and other '-omic' events that promote and sustain Ewing pathogenesis, the use of nascent biologically targeted therapeutics is on the horizon. Understanding how and when to integrate such therapies into clinical practice, although challenging, may lead to a paradigm shift towards more personalized therapy.

AB - With an improved understanding of the genome, transcriptome, proteome, and other '-omic' events that promote and sustain Ewing pathogenesis, the use of nascent biologically targeted therapeutics is on the horizon. Understanding how and when to integrate such therapies into clinical practice, although challenging, may lead to a paradigm shift towards more personalized therapy.

KW - Biomarkers

KW - Cancer

KW - Ewing's sarcoma

KW - IGF-1R

KW - Molecular markers

KW - Phase II trials

KW - Prognosis

KW - Sarcoma

KW - Staging

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=47249160783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249160783&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328303ba1d

DO - 10.1097/CCO.0b013e328303ba1d

M3 - Review article

C2 - 18525337

AN - SCOPUS:47249160783

SN - 1040-8746

VL - 20

SP - 412

EP - 418

JO - Current opinion in oncology

JF - Current opinion in oncology

IS - 4

ER -

Ewing sarcoma: Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this